Copyright © 2003 by the European Society of Cardiology.
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA
a Department of Cardiology, Thoraxcentre, Erasmus Medical Centre Rotterdam, Rotterdam,The Netherlands
b Stanford University School of Medicine, California, USA
c Kerckhoff Heart Center, Bad-Neuheim, Germany
d The Tenon Hospital, Paris, France
e Hospital De Weezenlanden, Zwolle, The Netherlands
f Medical Centre Alkmaar, Alkmaar, The Netherlands
Received April 29, 2003; accepted May 1, 2003 * Correspondence: Prof. Dr Maarten L. Simoons, Thoraxcentre, Department of Cardiology, Erasmus Medical Centre Rotterdam: room H560: Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
Aims Treatment with the glycoprotein IIb/IIIa receptor antagonist abciximab before and during coronary intervention in refractory unstable angina improves early outcome. We collected 4-year follow-up data to assess whether this benefit is sustained. Additionally, we investigated the predictive value of baseline troponin T and CRP for long-term cardiovascular events.
Methods and Results Of 1265 patients enrolled in the CAPTURE trial follow-up was available in 94% of the patients alive after 6 months (median 48 months). Survival was similar in both groups. Both elevated troponin T and CRP were associated with impaired outcome, independently of other established risk factors, but with a different time course. Elevated troponin was associated with increased procedure related risk, and elevated CRP with increased risk for subsequent events. Lower rates of the composite end-point of death or myocardial infarction with abciximab vs. placebo were sustained during long-term follow up: 15.7% vs 17.2% at 4 years (P=ns), particularly in patients with elevated troponin T: 16.9% with abciximab vs 28.4% with placebo: P=0.015. Elevated CRP was not associated with specific benefit of abciximab.
Conclusion Troponin T as a marker of thrombosis and CRP as a marker of inflammation are independent predictors of impaired outcome at 4 years follow-up. The initial benefit from abciximab with regard to death and myocardial infarction was preserved at 4 years. No specific benefit with abciximab was observed for patients with elevated CRP, suggesting that a chronic inflammatory process is not affected by abciximab. In contrast the benefit of treatment in patients with elevated troponin T implies that the acute thrombotic process in refractory unstable angina is treated effectively.
Key Words: Glycoprotein IIb/IIIa receptor antagonist • unstable angina pectoris • troponin T • C-reactive protein • long-term follow-up
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition
- S Ounpuu and S Yusuf
EHJ 2003 24: 127-129.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  C. M. Westerhout, Y. Fu, M. S. Lauer, S. James, P. W. Armstrong, E. Al-Hattab, R. M. Califf, M. L. Simoons, L. Wallentin, E. Boersma, et al. Short- and Long-Term Risk Stratification in Acute Coronary Syndromes: The Added Value of Quantitative ST-Segment Depression and Multiple Biomarkers J. Am. Coll. Cardiol., September 5, 2006; 48(5): 939 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R L Kennedy and R F Harrison Identification of patients with evolving coronary syndromes by using statistical models with data from the time of presentation Heart, February 1, 2006; 92(2): 183 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lenderink, C. Heeschen, S. Fichtlscherer, S. Dimmeler, C. W. Hamm, A. M. Zeiher, M. L. Simoons, E. Boersma, and for the CAPTURE Investigators Elevated Placental Growth Factor Levels Are Associated With Adverse Outcomes at Four-Year Follow-Up in Patients With Acute Coronary Syndromes J. Am. Coll. Cardiol., January 17, 2006; 47(2): 307 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Saleh, B. Svane, L.-O. Hansson, J. Jensen, T. Nilsson, O. Danielsson, and P. Tornvall Response of Serum C-Reactive Protein to Percutaneous Coronary Intervention Has Prognostic Value Clin. Chem., November 1, 2005; 51(11): 2124 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Large Contemporary management of acute coronary syndrome Postgrad. Med. J., April 1, 2005; 81(954): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.M. Hirschfield and M.B. Pepys C-reactive protein and cardiovascular disease: new insights from an old molecule QJM, November 1, 2003; 96(11): 793 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baldus, C. Heeschen, T. Meinertz, A. M. Zeiher, J. P. Eiserich, T. Munzel, M. L. Simoons, C. W. Hamm, and on behalf of the CAPTURE Investigators Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes Circulation, September 23, 2003; 108(12): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.M Califf Cardiac markers in acute coronary syndromes--refining our knowledge Eur. Heart J., January 2, 2003; 24(2): 136 - 137. [Full Text] [PDF]
|
|